Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026)
Relay Therapeutics' (RLAY) quarterly EBITDA Margin came in at 2619.67% in Q1 2026, down 151446.0% year-on-year from N/an in Q1 2025, and down 202.45% on a QoQ basis from 866.14% in Q4 2025.
Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of EBITDA Margin data on file, last reported at 2619.67% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 151446.0% year-over-year to 2619.67% in Q1 2026; TTM through Mar 2026 was 2776.6%, a 200233.0% increase from a year earlier, with the FY2025 full-year figure at 1971.59%, up 175048.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 2619.67%, down from 866.14% in the prior quarter.
- Over the last five years, EBITDA Margin for RLAY reached as high as 9219600.0% in Q4 2023 and fell as low as 89117.65% in Q2 2023.
- Historically, EBITDA Margin has averaged 690655.84% across 5 years, with a median of 11351.11% in 2025.
- On a YoY basis, EBITDA Margin climbed as much as 924839486 bps in 2023 and fell as far as 6779956 bps in 2023.
- Year by year, EBITDA Margin stood at 28794.86% in 2022, then soared by 32118 bps to 9219600.0% in 2023, then sank by 100 bps to 903.0% in 2024, then climbed by 4 bps to 866.14% in 2025, then slumped by 202 bps to 2619.67% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 2619.67% in Q1 2026, 866.14% in Q4 2025, and 11351.11% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Relay Therapeutics | 3.31 Bn | 3.31 Bn | - | -2,619.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,619.67% |
| Dec 31, 2025 | -866.14% |
| Jun 30, 2025 | -11,351.11% |
| Mar 31, 2025 | -1,105.21% |
| Mar 31, 2024 | -903.00% |
| Dec 31, 2023 | 9,219,600.00% |
| Sep 30, 2023 | -291.95% |
| Jun 30, 2023 | -89,117.65% |
| Mar 31, 2023 | -44,768.58% |
| Dec 31, 2022 | -28,794.86% |
| Sep 30, 2022 | -24,968.60% |
| Jun 30, 2022 | -21,318.08% |
| Mar 31, 2022 | -14,969.21% |
| Dec 31, 2021 | -11,944.09% |
| Sep 30, 2021 | -9,157.66% |
| Jun 30, 2021 | -22,936.02% |
| Mar 31, 2021 | -4,454.31% |